
FDA grants Abbott Emergency Use Authorization for another COVID-19 antibody test
pharmafile | May 12, 2020 | News story | Manufacturing and Production | COVID, COVID-19, coronavirus, pandemic, tests
The FDA has given Emergency Use Authorisation for another COVID-19 diagnostics test for antibodies from Abbott Laboratories.
With this approval, Abbott will have the ability to produce 30 million antibody tests and ship them across the globe by May. It will carry this out through its ARCHITECT and Alinity I platforms and aims to have 60 million tests produced by June.
This action by the FDA follows a previous emergency authorization last month for another Abbott antibody blood test, which has been shipped to the US, UK, India, Italy and Spain. The FDA has now tightened its regulationd for approving these tests, after multiple versions hit the market that were either flawed or did not meet standards that the agency has in place.
So far, this is Abbott’s fourth test to get Emergency Use Authorization by the FDA, and it’s seeking approval by the European Medicines Agency so it can be marketed in Europe. Robert B. Ford, the President and CEO of the company, commented on the tests and said: “Having more options of highly reliable tests across our platforms will help healthcare workers and health officials as they conduct broad scale testing for Covid-19.”
So far Abbott has shipped 1.4 million of its rapid ID NOW tests and is currently manufacturing 50,000 tests per day.
Conor Kavanagh
Related Content

COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …






